Liraglutide Cost in Wyoming 2026: Cash Pay, Medicaid, and Compounded Options

Is there a generic version of liraglutide?

No. As of this review, Novo Nordisk holds the only FDA-approved liraglutide products on the U.S. market: Victoza for type 2 diabetes and Saxenda for chronic weight management. When people search for "generic liraglutide," they are usually looking for one of two things: a lower-cost compounded version made by a licensed pharmacy, or a future generic entrant once patent and exclusivity protections lapse. Neither is the same as an FDA-approved generic copy that has gone through bioequivalence review.

Compounded liraglutide is legally available through 503A compounding pharmacies, which prepare a patient-specific formulation under a valid prescription from a licensed prescriber. This is different from a 503B outsourcing facility, which operates under stricter manufacturing standards but can generally only compound a drug that is on the FDA's shortage list or meets other narrow criteria. Whether liraglutide currently appears on the FDA shortage list can change month to month, so that status should be checked directly rather than assumed from an older reference.

What liraglutide actually costs, and why you should verify any number below

Manufacturer list price, insurance copay after prior authorization, cash price at retail, and compounded pharmacy price are four different numbers, and each moves independently. List prices are set by the manufacturer and change periodically. Cash and discount-card prices vary by pharmacy and region and shift with competition from newer GLP-1 products. Compounded pharmacy prices are set individually by each pharmacy and are not published in a central database.

Reported patient experiences generally place manufacturer list price for Victoza or Saxenda in the four-figure monthly range, cash and discount-card prices somewhat lower, and compounded 503A pricing well below both. None of those figures could be confirmed against a Wyoming-specific, dated source for this article, so they are not stated here as fixed numbers. Before quoting a price to a patient or publishing one, get a same-day quote from the specific Wyoming pharmacy, discount card platform, or compounding pharmacy involved. The verification checklist below gives a structured way to do that.

Patients on a high-deductible health plan should also expect to pay close to the cash price until the deductible is met, even with active insurance on file.

Wyoming Medicaid and liraglutide coverage

Wyoming Medicaid's current formulary status for liraglutide was not confirmed against a dated, Wyoming-specific source for this review and should not be treated as settled. State Medicaid coverage of GLP-1 receptor agonists for weight management and diabetes has been an area of active change nationally, with some states adding coverage under updated obesity-treatment guidance and others maintaining restrictions. The only reliable way to know Wyoming's current position is to check the state Medicaid Preferred Drug List directly, since a fact stated in an older article can become outdated without warning.

According to the American Diabetes Association's Standards of Care, GLP-1 receptor agonists with proven cardiovascular benefits are recommended for adults with type 2 diabetes who have established or high cardiovascular risk [1]. While such guidelines may encourage wider coverage consideration, professional recommendations differ from state formulary determinations and should be evaluated separately.

Patients enrolled in Wyoming Medicaid who cannot get liraglutide through their plan may be eligible for Novo Nordisk's patient assistance program for households under a defined income threshold relative to the federal poverty level; current income thresholds and processing times should be checked at novocare.com rather than assumed to be unchanged from a prior year.

Commercial insurance and prior authorization

Most commercial plans that require coverage of GLP-1 receptor agonists apply prior authorization, and the criteria typically differ between the type 2 diabetes indication (Victoza) and the weight-management indication (Saxenda). For Victoza, insurers commonly want a confirmed type 2 diabetes diagnosis and documentation that a first-line agent such as metformin was tried or contraindicated. For Saxenda, insurers commonly want a qualifying BMI, or a lower BMI plus a weight-related comorbidity such as hypertension or dyslipidemia, along with documentation of a supervised diet and exercise program.

Which specific insurers are active in Wyoming, and each plan's exact PA criteria, copay tier, and formulary exclusions, are not stable facts that hold across all plan years. Confirm the current criteria directly with the specific plan's formulary document rather than relying on a general description, since an outdated PA requirement can cost weeks of delay for a patient.

Compounded liraglutide through a 503A pharmacy

Compounded liraglutide is legal in Wyoming through a state-licensed 503A compounding pharmacy operating under a valid, patient-specific prescription, under the federal compounding framework governing 503A pharmacies. This is meaningfully different from an FDA-approved product. Compounded liraglutide has not gone through FDA bioequivalence testing, and potency, sterility, and stability depend on that specific pharmacy's quality controls rather than FDA batch certification.

States commonly require an out-of-state compounding pharmacy to hold a nonresident pharmacy permit before dispensing to their residents. Confirm this requirement and the pharmacy's current permit status with the Wyoming Board of Pharmacy before ordering from an online compounding pharmacy, rather than assuming any pharmacy that advertises to Wyoming patients is properly licensed to do so.

Telehealth prescribing

Telehealth prescribing of liraglutide is broadly permitted across most states once a clinician establishes a valid patient-provider relationship, commonly through a synchronous video visit, without requiring a prior in-person exam. Wyoming's exact current statutory and Board of Medicine requirements should be verified directly rather than cited from a fixed reference, since telehealth practice rules are an area state legislatures and boards revisit periodically.

For a weight-management prescription, the FDA label for Saxenda specifies qualifying criteria of a BMI of 30 or above, or 27 or above with a weight-related comorbidity such as controlled hypertension, type 2 diabetes, or dyslipidemia [3]. A prescriber should document that criterion regardless of whether the visit happens in person or by telehealth.

Clinical background

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist given as a once-daily subcutaneous injection. The FDA approved the 1.2 mg and 1.8 mg doses (Victoza) for type 2 diabetes in 2010, and the 3 mg dose (Saxenda) for chronic weight management in 2014 [3].

In the SCALE Obesity and Prediabetes trial (n=3,731), liraglutide 3 mg achieved mean weight loss of 8.4 kg at 56 weeks versus 2.8 kg with placebo, with 63.2% of liraglutide recipients reaching at least 5% weight loss compared to 27.1% on placebo [5]. The FDA label specifies that if patients fail to achieve at least 4% weight loss from baseline by week 16, the medication is unlikely to yield clinically meaningful results and should be discontinued [3].

The LEADER trial (n=9,340) found that liraglutide 1.8 mg reduced major adverse cardiovascular events by 13% relative to placebo in adults with type 2 diabetes and high cardiovascular risk (hazard ratio 0.87, 95% CI 0.78 to 0.97) [6]. That cardiovascular outcome data is a reason some clinicians continue to favor liraglutide for patients with established cardiovascular disease even as once-weekly GLP-1 agents have become more widely used.

Newer once-weekly agents have taken meaningful market share from liraglutide. The STEP 1 trial of semaglutide 2.4 mg (n=1,961) found 14.9% mean weight loss at 68 weeks versus 2.4% on placebo, a larger effect than liraglutide produced in its own trials, though the two drugs were not compared head-to-head in a single trial cited here [7]. Tirzepatide has shown larger effects still in its own trial program. Cost, dosing frequency, insurance formulary placement, and individual tolerability all factor into which agent a clinician and patient choose, and none of those trials establishes that one drug is the right choice for a given Wyoming patient without an individualized evaluation.

Dulaglutide and other older GLP-1 agents remain options for patients whose main goal is glycemic control rather than substantial weight loss. Metformin remains the standard first-line oral agent for type 2 diabetes and is broadly covered by state Medicaid programs, including Wyoming's.

Practical steps for lowering cost

• Confirm which FDA-approved indication applies. A type 2 diabetes diagnosis opens the Victoza pathway, which insurers often treat with less restrictive prior authorization than the obesity indication.
• If the goal is weight management, document any qualifying comorbidity at the prescribing visit, since that documentation is often what a PA reviewer is checking for.
• Check the specific employer or individual plan's formulary document for a GLP-1 or weight-management drug exclusion before submitting a prior authorization request, since some plans carve these out entirely regardless of medical necessity.
• If prior authorization is denied, ask the prescriber about a formal appeal citing the ADA Standards of Care and relevant cardiovascular outcome data where applicable. Appeal success rates vary by plan and were not available from a Wyoming-specific source for this article.
• If insurance access is not workable, get a same-day quote from a licensed Wyoming-permitted 503A compounding pharmacy and confirm both its permit status and its quality practices before committing.
• Check Novo Nordisk's current savings card and patient assistance program terms at novocare.com. Manufacturer savings cards generally cannot be used with Medicare, Medicaid, or other government coverage.

Verification checklist: stable facts versus facts that change

Use this before publishing, prescribing around, or quoting any figure in this article. The left column rarely changes and can generally be trusted from a recent citation. The right column changes on its own schedule (monthly, per plan year, or per pharmacy) and should be confirmed the same day it is used.